hit counter

Personalized Care for Young-Onset Diabetes Eased Distress, Not Complications

MHD card showing a DNA helix that turns into a glucose curve flowing into a clinician's tablet with a personalized report, illustrating the PRISM trial in which personalized care for young-onset diabetes eased diabetes distress but did not reduce complications.

Adults in Hong Kong who developed diabetes by age 40 reported less diabetes distress after a year of personalized care that included genetic and biomarker testing. Over 3 years, though, the extra care did not lower their rate of diabetes complications.1 Research Highlights A large randomized trial: the PRISM trial assigned 884 Chinese adults with …

Read more

PReDicT Antidepressant Algorithm Cost-Effectiveness Was Uncertain

MHD featured image for PReDicT antidepressant algorithm cost-effectiveness.

A 913-person economic evaluation of the PReDicT antidepressant algorithm found nearly identical EQ-5D quality-of-life gains vs. treatment as usual (+0.139 vs. +0.140) and nearly identical societal cost reductions (−€2,589 vs. −€2,602), while cost-effectiveness probabilities were only 46% to 59% at trial level but exceeded 80% in the UK.1 The algorithm signal was country-specific and capability-weighted, …

Read more

Parkinson’s Metabolite Biomarkers Split 3 Patient Groups

MHD featured image for Parkinson's disease metabolite biomarkers and patient metabolic subgroups.

A 2026 Parkinson’s disease study used gene-expression data and genome-scale metabolic modeling to predict patient-level metabolite patterns, then separated 104 patients into 3 metabolic subgroups that were partly reproduced in an independent 81-patient validation dataset. Research Highlights Patient-level modeling found heterogeneity: Abdik et al. predicted secretion tendencies for 802 analyzable metabolites across 104 postmortem substantia …

Read more